胰高血糖素样肽-1受体激动剂在肥胖治疗中的研究进展
Research progress of glucagon-like peptide-1 receptor agonists in the treatment of obesity
吕美锋 1张雅慧 2冷冰 2聂瑞芳 2沈承武 2于恒彩2
作者信息
- 1. 山东第一医科大学附属省立医院药学部,山东济南 250021;济南市第二妇幼保健院药剂科,山东济南 250021
- 2. 山东第一医科大学附属省立医院药学部,山东济南 250021
- 折叠
摘要
肥胖是一种复杂的慢性疾病,随着生活水平的提高,全球和中国超重和肥胖的人数越来越多.肥胖可以引发一系列健康问题,如心血管疾病、2型糖尿病、卒中,甚至肿瘤及社会心理疾病.目前治疗肥胖的方式包括饮食与运动,以及在此基础上的药物治疗和手术治疗.已上市的减重药物如芬特明/托吡酯、纳曲酮/安非他酮、氯卡色林、奥利司他等因各种严重不良反应限制了其临床使用,胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RAs)因减重效果优异且安全性好而备受关注.该文就美国食品药品监督管理局已批准减重适应证的GLP-1RA类药物利拉鲁肽和司美格鲁肽及国内外在研GLP-1RA类减重药物的疗效和安全性,以及GLP-1RA类减重药在我国的批准使用情况进行综述,以期为广大医务工作者提供参考.
Abstract
Obesity is a complex chronic disease.With the improvement of living standards,the amount of overweight and obese people has steadily increased throughout the world and in China.Obesity can lead to a series of health problems,such as car diovascular disease,type 2 diabetes,stroke and even cancer and psychosocial disorders.At present,the treatments of obesity con-tain behavioural change(e.g.,nutrition and exercise)and adjunctive therapies,including pharmacologic and surgical interven-tions.The clinical use of anti-obesity drugs on the market,such as phentermine/topiramate,naltrexone/bupropion,lorcaserin,and orlistat,is limited because of various serious adverse events.Glucagon-likepeptide-1 receptor agonists(GLP-1RAs)are increasingly being appreciated due to its excellent efficacy on weight loss and good safety.This article summarizes the efficacy and safety of Liraglutide and Semaglutide,which have been approved by the food and drug administration for weight loss medication as GLP-1RAs,and GLP-1RA weight loss medication under development at home and abroad,as well as the approval and usage of GLP-1RA weight loss medication in China.This review may serve as a reference for the majority of health workers.
关键词
肥胖/减重/胰高血糖素样肽-1受体激动剂/研究进展Key words
obesity/weight loss/glucagon-like peptide-1 receptor agonist/research progress引用本文复制引用
基金项目
山东省药学会科研项目(SDSYXH-KY-202306)
出版年
2024
NETL
NSTL
万方数据